Three Takeda diabetes products get CHMP green light
This article was originally published in Scrip
Executive Summary
The European approval gate has been opened for three of Takeda's new type 2 diabetes therapies, which have today received positive opinions from the EMA's Committee for Medicinal Products for Human Use (CHMP).
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.